Physician profile
Daniel Miles Libby
NPI 1114033057
$4,294.43
in general payments reported to CMS, 2019-2025
21 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $387 · 2021: $219 · 2022: $311 · 2023: $1,301 · 2024: $664 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.82 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,353.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Insmed, INC. | $969.41 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.98 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Electromed, INC. | $226.80 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $183.66 | 2019-2024 | Uptravi, Opsumit |
| Amgen INC. | $156.11 | 2023-2024 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $148.87 | 2019-2024 | Fasenra, Symbicort, Tezspire |
| Philips North America LLC | $143.41 | 2022-2025 | Vest Therapy Und |
| Pulmonx Corporation | $141.04 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Regeneron Healthcare Solutions, INC. | $135.03 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $117.70 | 2020-2024 | Glassia, Aralast |
| Genzyme Corporation | $110.34 | 2019-2024 | |
| Baxter Healthcare | $80.58 | 2023-2024 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $64.29 | 2019 | |
| Mylan Specialty L.P. | $38.76 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $38.30 | 2019 | |
| Merck Sharp & Dohme LLC | $33.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.41 | 2023 | |
| Verona Pharma, INC. | $30.03 | 2025 | Ohtuvayre |
| 3b Medical, INC. | $19.68 | 2025 | Luna |
| Paratek Pharmaceuticals, INC. | $18.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Libby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.